1,267 posters, 47 videos, 13 topics, 4 sessions, 853 authors

SOHO 2026 Annual Meeting

September 9 - 12, 2026 | George R. Brown Convention Center, Houston, Texas

Authors

Showing 3 results for author "Javier Munoz".

$Thumbnail for Golcadomide, a Potential First-in-Class, Oral Celmod ± Rituximab in the Phase 1/2 CC-99282-NHL-001 Study: Long-Term Follow-Up Results of Patients With Relapsed/Refractory Follicular Lymphoma$

IBCL - 141

Golcadomide, a Potential First-in-Class, Oral Celmod ± Rituximab in the Phase 1/2 CC-99282-NHL-001 Study: Long-Term Follow-Up Results of Patients With Relapsed/Refractory Follicular Lymphoma

Javier Munoz

Poster Presenter: Javier Munoz

$Thumbnail for Treatment Patterns and Clinical Outcomes Among Patients With Treatment-Naοve and Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL) in Community Practice Between 2020 and 2025$

MCL - 1296

Treatment Patterns and Clinical Outcomes Among Patients With Treatment-Naοve and Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL) in Community Practice Between 2020 and 2025

Javier Munoz

Poster Presenter: Javier Munoz

Video

Authors

Golcadomide, a Potential First-in-Class, Oral Celmod ± Rituximab in the Phase 1/2 CC-99282-NHL-001 Study: Long-Term Follow-Up Results of Patients With Relapsed/Refractory Follicular Lymphoma

Treatment Patterns and Clinical Outcomes Among Patients With Treatment-Naοve and Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL) in Community Practice Between 2020 and 2025

Clinical Outcomes Among Patients With Relapsed/Refractory Mantle Cell Lymphoma Receiving Zanubrutinib or Acalabrutinib in Real-World Practice in the United States